PMC:7414629 / 5788-7055 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T59","span":{"begin":352,"end":369},"obj":"Body_part"},{"id":"T60","span":{"begin":423,"end":440},"obj":"Body_part"},{"id":"T61","span":{"begin":482,"end":487},"obj":"Body_part"},{"id":"T62","span":{"begin":531,"end":543},"obj":"Body_part"},{"id":"T63","span":{"begin":627,"end":632},"obj":"Body_part"},{"id":"T64","span":{"begin":1134,"end":1139},"obj":"Body_part"}],"attributes":[{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma7183"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma7184"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma7181"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma50868"},{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma7181"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T34","span":{"begin":452,"end":461},"obj":"Body_part"},{"id":"T35","span":{"begin":482,"end":487},"obj":"Body_part"},{"id":"T36","span":{"begin":531,"end":543},"obj":"Body_part"},{"id":"T37","span":{"begin":538,"end":543},"obj":"Body_part"},{"id":"T38","span":{"begin":627,"end":632},"obj":"Body_part"},{"id":"T39","span":{"begin":1134,"end":1139},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"uberon_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/UBERON_2000106"},{"id":"A35","pred":"uberon_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/UBERON_0002100"},{"id":"A36","pred":"uberon_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/UBERON_0001647"},{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"A38","pred":"uberon_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0002100"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":531,"end":549},"obj":"Disease"},{"id":"T52","span":{"begin":544,"end":549},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005665"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0006496"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T85","span":{"begin":173,"end":174},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T86","span":{"begin":272,"end":273},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T87","span":{"begin":306,"end":309},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T88","span":{"begin":358,"end":369},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T89","span":{"begin":374,"end":377},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T90","span":{"begin":429,"end":440},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T91","span":{"begin":480,"end":481},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T92","span":{"begin":538,"end":543},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T93","span":{"begin":613,"end":614},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T94","span":{"begin":627,"end":632},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T95","span":{"begin":627,"end":632},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T96","span":{"begin":627,"end":632},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T97","span":{"begin":627,"end":632},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T98","span":{"begin":658,"end":659},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T99","span":{"begin":753,"end":754},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T100","span":{"begin":872,"end":873},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T101","span":{"begin":982,"end":983},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T102","span":{"begin":1246,"end":1247},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PubTator","denotations":[{"id":"182","span":{"begin":815,"end":818},"obj":"Gene"},{"id":"183","span":{"begin":861,"end":864},"obj":"Gene"},{"id":"184","span":{"begin":837,"end":840},"obj":"Gene"},{"id":"185","span":{"begin":1195,"end":1198},"obj":"Gene"},{"id":"186","span":{"begin":141,"end":144},"obj":"Gene"},{"id":"187","span":{"begin":4,"end":11},"obj":"Species"},{"id":"188","span":{"begin":124,"end":131},"obj":"Species"},{"id":"189","span":{"begin":254,"end":261},"obj":"Species"},{"id":"190","span":{"begin":1056,"end":1063},"obj":"Species"},{"id":"191","span":{"begin":290,"end":302},"obj":"Disease"},{"id":"192","span":{"begin":531,"end":549},"obj":"Disease"},{"id":"193","span":{"begin":667,"end":692},"obj":"Disease"},{"id":"194","span":{"begin":945,"end":959},"obj":"Disease"},{"id":"195","span":{"begin":964,"end":976},"obj":"Disease"}],"attributes":[{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"Gene:2023"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Gene:2023"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"Gene:2023"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"Gene:2023"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"Gene:2023"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"Tax:9606"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"Tax:9606"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"Tax:9606"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"Tax:9606"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"MESH:C565722"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:D005158"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:D006261"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:D005158"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:C565722"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T26","span":{"begin":290,"end":302},"obj":"Phenotype"},{"id":"T27","span":{"begin":531,"end":549},"obj":"Phenotype"},{"id":"T28","span":{"begin":945,"end":959},"obj":"Phenotype"},{"id":"T29","span":{"begin":964,"end":976},"obj":"Phenotype"}],"attributes":[{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0002273"},{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0010628"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0007209"},{"id":"A29","pred":"hp_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/HP_0002273"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-sentences","denotations":[{"id":"T49","span":{"begin":0,"end":119},"obj":"Sentence"},{"id":"T50","span":{"begin":120,"end":249},"obj":"Sentence"},{"id":"T51","span":{"begin":250,"end":576},"obj":"Sentence"},{"id":"T52","span":{"begin":577,"end":741},"obj":"Sentence"},{"id":"T53","span":{"begin":742,"end":819},"obj":"Sentence"},{"id":"T54","span":{"begin":820,"end":856},"obj":"Sentence"},{"id":"T55","span":{"begin":857,"end":1051},"obj":"Sentence"},{"id":"T56","span":{"begin":1052,"end":1152},"obj":"Sentence"},{"id":"T57","span":{"begin":1153,"end":1267},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T110","span":{"begin":429,"end":440},"obj":"UBERON:0003632"},{"id":"T111","span":{"begin":482,"end":487},"obj":"UBERON:0002100"},{"id":"T112","span":{"begin":520,"end":530},"obj":"UBERON:0001021"},{"id":"T113","span":{"begin":531,"end":543},"obj":"UBERON:0001647"},{"id":"T114","span":{"begin":627,"end":632},"obj":"UBERON:0000948"},{"id":"T115","span":{"begin":667,"end":678},"obj":"GO:0031649"},{"id":"T116","span":{"begin":679,"end":692},"obj":"GO:0065007"},{"id":"T117","span":{"begin":945,"end":951},"obj":"UBERON:0001456"},{"id":"T118","span":{"begin":1107,"end":1118},"obj":"GO:0042592"},{"id":"T119","span":{"begin":1134,"end":1139},"obj":"UBERON:0002100"},{"id":"T120","span":{"begin":1225,"end":1231},"obj":"UBERON:0002405"}],"text":"The patient was admitted to ICU and further treatment was carried out in strict compliance with the isolation measures. Our patient received PPh every 2 days, and there was a clinical deterioration in spite of this treatment during the first 5 days. The patient developed a flaccid, severe tetraparesis of 3/5 in the proximal, 1/5 in the distal of the upper extremities and 3/5 in the proximal and 0/5 in the distal of the lower extremities for dorsal extension, 2/5 for flexion, a trunk instability, and also bilateral peripheral facial nerve palsy (House–Brackmann grade 5). There were autonomous symptoms with a tachycardic heart action until 120/min and a severe orthostatic dysregulation, with no further possibility of sitting upright. She showed a tendency for clinical improvement after the third course of PPh. Seven courses of PPh were performed. The PPh caused a slightly further clinical improvement with asymmetrical improvement of facial paresis and tetraparesis, but a clinical stagnation of the improvement during the following 5 days. The patient was still unable to sit upright because of orthostatic collapsing and trunk instability. Therefore, we added 5 days after the last PPh 0.40 g/kg/day intravenous immune globulins for a duration of 5 days."}